Dr. Raphael Mechoulam, an Israel bio-chemist and trailblazing cannabis researcher, announced last month a process to produce synthetic cannabinoid acids – chemical compounds that may be more stable than their plant-based counterparts.
“This is exciting and unprecedented research,” said Dr. Mechoulam said in a press release. “We have taken the unstable molecules of the cannabis plant and synthesized them to provide a stable, consistent basis for researching new therapies across a wide range of medical needs – from CNS disorders to inflammation, and many more.”
Dr. Mechaloum has been on the forefront of cannabis research for sixty years.
From 1963-65, Mechoulam successfully isolated and synthesized cannabidiol (CBD) and tetrahydrocannabinol (THC). In 1992, Mechoulam identified the endocannabinoids anandamide and 2-AG, which led to the discovery of the endocannabinoid system (ECS).
Looking to the Future
Now, Dr. Mechoulam and his team have created HU-380, an acid methyl ester that mimics the effects of cannabidiolic acid, or CBDA. CBDA is potent, but unstable. Slight temperature changes or exposure to ultraviolet light are enough to break down the acid.
“This particular compound…enhances serotonin activation,” explained Mechoulam in a keynote address at CannaMed, a cannabis research conference. “Serotonin and dopamine, these are the two